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Background: Human papillomavirus (HPV)-positive oropharyngeal cancer primarily affects working-age adults.
Chemotherapy and radiation (CTRT) used to treat this disease may adversely impact a survivors’ ability to work after
treatment.
Methods: We surveyed participants with HPV-positive oropharyngeal cancer who completed CTRT regarding
employment. We examined the associations between 1) sociodemographic and clinical factors and employment
outcomes, and 2) health-related quality of life and satisfaction with ability to work.
Results: 102 participants were employed full-time at diagnosis for pay and surveyed at a median of 23 months
post-CTRT (range 12–57 months). The median age at diagnosis was 57 years (range 25–76 years). During CTRT,
8 % stopped working permanently, 89 % took time off or reduced responsibility but later returned, and 3 %
reported no change. For those who took time off but returned, median time to return to work was 14.5 weeks.
In multivariable analysis, younger age predicted for needing more than the median time off. At time of survey,
85 % participants were working, 7 % had retired, and 8 % were not working for other reasons. Seventeen
percent of participants were not satisfied with their current ability to work, which was associated with poorer
health-related quality of life and persistent treatment toxicities (p < 0.001).
Conclusions: CTRT interrupts employment in the majority of working patients with HPV-positive oropharyngeal
cancer but most return. However, treatment-related toxicities might lead to dissatisfaction with ability to work.
Keywords: Head and neck cancer, Employment, Survivorship, Quality of life, ChemoradiationBackground
The incidence of oropharyngeal cancer, a type of head
and neck cancer, is rising despite declining rates of
all tobacco-related malignancies in the United States
[1, 2]. The rise in rates of oropharyngeal cancer is
explained by an increase in cancers associated with
human papillomavirus (HPV) [3]. Nearly 80 % of
patients diagnosed with HPV-positive oropharyngeal* Correspondence: baxis@mskcc.org
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be non-smokers, non-drinkers, and generally healthier
than patients with non-HPV-positive head and neck
cancer [4–9]. They are also younger, with a median
age at diagnosis of 57 years, about 5 years younger
than head and neck cancer unrelated to HPV [1, 4].
Despite the growing appreciation for the difference in
biology and better observed disease control in patients
with HPV-positive compared to HPV-negative head and
neck tumors, the management of oropharyngeal cancers
is currently the same for patients regardless of HPV-
status. Oropharyngeal cancer presents at a locally ad-
vanced stage in more than 70 % of patients and is often
treated with a multimodality approach employing a
course of definitive concurrent chemotherapy andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Table 1 Characteristics of the Cohort
Characteristic Number
Total 102
Months since diagnosis, median (range) 23 (14–60)
























Induction + CTRT 8
CTRT + surgery 4
Chemotherapy
High dose cisplatin 67
Other chemotherapy 35
Notes
Percentages not provided given N close to 100
aAge-adjusted Charlson comorbidity score calculated including localized
solid tumor
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Cisplatin remains the most studied and most commonly
used radiation-sensitizing chemotherapy for the manage-
ment of head and neck cancer, and the majority of head
and neck cancers are treated with intensity-modulated
radiation therapy (IMRT) [12–14].
The acute toxicities resulting from CTRT for head and
neck cancer can include mucositis, difficulty with swal-
lowing, pain requiring narcotic medications, anorexia,
fatigue, thick saliva, nausea and vomiting and substantial
weight loss. Taken together these toxicities contribute to
a decline in general functional capacity [15, 16]. Longitu-
dinal studies have reported that patients with head and
neck cancer undergoing CTRT therapy can experience a
clinically significant decline in quality of life and func-
tioning and that recovery is a slow process which
continues up to 12 months post treatment completion
[17, 18]. Paradoxically, these effects may be amplified in
the generally younger and otherwise healthier oropharyn-
geal cancer patients with HPV-positive tumors. In a recent
report of oropharyngeal cancer patients treated with
CTRT, patients with HPV-positive tumors had better
baseline health-related quality of life, but a more rapid
decline during treatment compared to patients with HPV-
negative tumors. Both groups, however, showed substan-
tial recovery by 12 months post-treatment, suggesting that
the acute impact of CTRT is experienced more signifi-
cantly by the younger, healthier patients [19].
Poorer health-related quality of life in patients with
HPV-positive tumors may be particularly relevant to
employment. Prior reports suggest that compared to sur-
vivors of other solid tumors, patients treated for head
and neck cancer have difficulty returning to work after
cancer treatment [20–23]. Some explanations for poorer
occupational outcomes are receipt of multimodality ther-
apy, post-treatment impact on swallowing and speaking,
and possible disfigurement resulting from treatment
[24–26]. However, because we do not yet fully understand
their long-term health outcomes, it is unclear if these
findings apply to the emerging cohort of working-age
HPV-positive survivors.
Given the acute functional deterioration experienced
during and after CTRT, and the increasing incidence of
this diagnosis in working-age adults, our objective was
to assess work interruption and employment outcomes
in HPV-positive oropharyngeal cancer patients employed
at diagnosis. We hypothesized that younger age and the
receipt of high-dose cisplatin would be associated with
more work interruption in this population.
Results
The study sample included 102 patients who had been
diagnosed with HPV-positive oropharyngeal cancer at
least a year prior, who were working full-time atdiagnosis, and who completed a survey about employment
and quality of life (Table 1). Ninety-four patients (92 %)
provided a job description, and the majority of these partic-
ipants (87 %) were employed in jobs most often conducted
in an office setting (Table 2). Participants were at a median
of 23 months from completion of treatment with CTRT
(range 12–57 months) at the time of the survey, and 94 %
were male. At time of diagnosis, the median age was
56 years (range 25–75 years) and 90 % had a Karnofsky
performance status (KPS) score of 90 %. A majority (85 %)
had stage IVA or IVB disease, and 49 % had tumors that
arose in the base of the tongue. All patients received
Table 2 Job category and work interruption during concurrent chemotherapy and radiation
Job category (example) Number Did not take time off Reduced hours Took time off, returned Took time off, never returned
N (%) N (%) N (%) Median time
off (weeks)
N (%)
Professional (attorney, psychologist) 53 2 (4) 9 (17) 38 (72) 15 4 (8)
Other officers & mgrs (plant manager,
postal supervisor)
9 1 (11) 2 (22) 6 (67) 12 0 (0)
Executives or senior officers (hotel owner,
bank executive)
8 0 (0) 2 (25) 6 (75) 14 0 (0)
Sales workers (real estate agent) 8 0 (0) 3 (38) 4 (50) 14 1 (12)
Craft worker (stage hand, iron worker) 6 0 (0) 1 (17) 4 (67) 6.5 1 (17)
Other 10 0 (0) 0 (0) 9 (90) 18 1 (10)
Not provided 8 0 (0) 1 (13) 6 (75) 9 1 (12)
Total 102 3 (3) 18 (18) 73 (71) 14.5 8 (8)
Notes
Row percentages add to 100 %
Jobs categorized using Unites States Equal Employment Opportunity Commission Job Classification Guide
Other includes job categories with <5 patients: administrative support workers (4), service workers (1), and technicians (3)
Based on n = 73 who provided information
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all patients were treated using IMRT. High-dose cisplatin
(100 mg/m2 every 3 weeks) was the most commonly used
regimen (66 % of participants).
Employment
Three (3 %) participants never reduced their work hours
or ever stopped working; 18 (18 %) were able to keep
working in some capacity during treatment; 73 (72 %)
stopped working but eventually returned; and 8 (8 %)
stopped working and never returned. Among those who
reduced their hours or took time off, the median time to
return to full-time work was 14.5 weeks, with a range of
1 to 52 weeks (Table 2). Forty-four patients (43 %) either
never returned to work or took more than the median
14.5 weeks off.
At the time of the survey, 87 (85 %) patients were
employed, with 82 working full-time and 5 working
part-time. Seven patients (7 %) had retired; their occupa-
tions were professionals (4), craft worker (1), an execu-
tive (1), and an administrative support worker included
as “Other” in Table 2 (1). Eight patients (8 %) were not
employed, and six of them had stopped working at time
of treatment. The remaining two returned to work but
then later stopped.
For the eight patients who did not return to work after
treatment was completed, no sociodemographic (age,
marital status), disease (stage or site), treatment (radi-
ation fields or chemotherapy) were associated with this
outcome in an unadjusted analysis. However, at the time
of the survey, older patients and those with higher
Charlson comorbidity scores at diagnosis were less likely
to be working (p < 0.05). In multivariable analysis, youn-
ger age at diagnosis was associated with taking off morethan the median 14.5 weeks (or not returning to work at
all) after treatment completion (p < 0.04).
Quality of life and satisfaction with ability to work
Overall, participants reported very high global quality of
life at the time of the survey. Mean global self-rated
health status on the EuroQol-5D Visual Analog Scale
(EQ-5D VAS) was 86 (standard deviation 13). Just over
half of the patients (55 %) reported no issues in the five
domains addressed by the EQ-5D which includes mobility,
self-care, usual activities, pain/discomfort and anxiety/de-
pression. However, 30 % reported some level of pain, and
22 % reported some level of anxiety. There were fewer
reports of difficulty with mobility (13 %), usual activities
(12 %) and self-care (3 %).
Of 101 patients who responded to a question regard-
ing satisfaction with ability to work at time of survey,
17 % reported dissatisfaction with their current ability to
work. In relation to current employment status, 7 of 82
patients working full-time (9 %), 3 of 5 patients working
part-time (60 %), 1 of 7 patients who retired (14 %), and
6 of 7 who were unemployed (86 %) reported dissatisfac-
tion with their ability to work.
Participants who were dissatisfied with their ability
to work reported more problems on the EQ-5D (p = 0.03)
and lower mean EQ-5D VAS scores (70 versus 89, p <
0.0001) compared to those who were satisfied with their
ability to work. Further, patients’ dissatisfaction with abil-
ity to work was associated with more severe late toxicities
resulting from CTRT (Fig. 1). Specifically, participants
who were dissatisfied with ability to work reported higher
scores on the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire Head
and Neck 35 module (EORTC QLQ-H&N35) for weight



















Mean score (high is worse)
Not satisfied Satisfied
Fig. 1 The European Organization for Research and Treatment of Cancer (EORTC) QLQ-H&N35 scale and single-item mean scores, by satisfaction
with ability to work. P values shown are from the Kruskal Wallace exact test and those marked *are statistically significant at P ≤ 0.01
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ill, sexuality, social contact, social eating, speech and
senses (p < .01).
When patients who were dissatisfied with their ability
to work (N = 17) were asked about reasons for their
dissatisfaction, most patients listed physical complaints
or cognitive impairment. Fatigue was the most commonly
listed reason (29 %) followed by memory loss and cogni-
tive decline (18 %), chronic neck pain (12 %), difficulty
speaking (12 %), unexplainable inability to work (12 %)
and hearing loss (6 %). One patient reported that his em-
ployer did not approve his leave of absence for treatment.
Discussion
This study highlights three important aspects of employ-
ment in survivors of HPV-positive oropharyngeal cancer
treated with definitive CTRT. The first is that the major-
ity of patients will be able to return to work following
treatment and will be satisfied with their ability to work.
The second is that younger age may be associated with
longer employment interruption following CTRT. And
the third conclusion is that symptoms related to treat-
ment linger well past treatment completion and are
associated with dissatisfaction with ability to work after
treatment completion. Notably, type of chemotherapy,primary tumor location, baseline functional status, and
sociodemographic variables were not associated with
whether the participant returned to work.
Employment and return to work after cancer treatment
are important issues for patients, not only because of the fi-
nancial implications but also due to the self-identity and
emotional well-being which can be associated with a job
[23, 27]. Depending on the cancer population, the effects of
cancer and its treatment on employment appear to be tran-
sient for the majority of patients, like the participants in
our study. However, the impact is more permanent for a
subset of survivors, which is consistent with our findings
where 8 patients never returned to work after treatment
completion [28, 29]. In a meta-analysis and meta-regression
of 36 studies, including 20,366 patients with many different
cancers and 157,603 age-matched controls, de Boer and
colleagues estimated a pooled relative risk (RR) of un-
employment of 1.37 compared to age-matched cancer-free
controls from the general population [29]. Yet, there was a
great deal of variability in employment status, treatments
and toxicities associated with post-treatment unemploy-
ment across the studies included in the pooled analysis
highlighting the heterogenous nature of cancer patients.
Across cancer types, education and occupation appear to
modify the effect of cancer on employment [20, 30]. For
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and colleagues reported that the rates of employment be-
tween cancer survivors 2–3 years after diagnosis was 9 %
lower than matched cancer-free controls (RR 0.88, 95 % CI
(0.86–0.90). However the difference was more pronounced
in patients with only grade 1–9 education (RR 0.81, 95 %
CI 0.78–0.84), and the difference was not significant in
patients with university education (RR 0.96, 95 % CI 0.93–
1.00) [31]. While we did not explicitly ask for educational
level in our survey, the occupations represented in our
participants are generally associated with higher educa-
tion and our findings of high return to work following
treatment completion are consistent with these prior
observations.
In prior studies in the United States and Europe, pa-
tients treated for head and neck cancer were more
likely to stop working and less likely to return to work
after treatment compared to most other solid tumors
[20, 22, 23, 25]. The association between job type and
employment seen in other cancers is present in head
and neck cancer survivors as well [26]. While we were
unable to assess the association of job type on employ-
ment outcomes within our population, even in this
study, where the majority of participants were employed
in desk jobs, treatment was associated with some level
of employment reduction, interruption, or discontinu-
ation in all but 3 participants. Interestingly, younger
age was associated with requiring longer employment
interruption despite expected better physiologic toler-
ance to treatment than older patients. Although this
study did not measure quality of life prospectively
during treatment, others have reported that the acute
toxicities of CTRT are more acutely experienced by
younger patients with higher rates of depression and
poor coping than older patients who might be physic-
ally less functional [32]. Our findings suggest that the
toxicity of CTRT is significant in all head and neck
cancer patients, regardless of the fact that patients
with HPV-positive disease present healthier than their
HPV-negative counterparts. However, despite needing
time off, it is possible that a younger and healthier
population is more likely to eventually recover and be
able to return to work than historical head and neck
cancer patients with HPV-negative tumors, explaining
at least some of the differences between our results and
prior studies on employment outcomes in the head and
neck cancer population. Wells et al. recently reported
that independent predictors of poorer quality of life in
long-term head and neck cancer survivors include
unemployment and younger age, but the relationship
between the two was not elucidated in this cross-sectional
survey either [33].
Only a few studies have evaluated both health-related
quality of life and employment outcomes among headand neck cancer survivors. They reported that a higher se-
verity of fatigue and oral dysfunction were associated with
unemployment [24, 25, 34, 35]. In our study population,
while most participants were able to return to work, the
presence of long-term toxicities of CTRT, including fa-
tigue, oral and social interaction symptoms, more than a
year after treatment completion were associated with dis-
satisfaction with ability to work, most commonly reported
by those unemployed at time of survey [24, 25, 35].
A limitation of this study is the high proportion of high-
level managers and professionals in our single-institution
study cohort. However, the epidemiology of HPV-positive
oropharyngeal cancer is emerging as a disease of patients
from higher socioeconomic status, and the employment
demographics of this population have not been previously
described [36, 37]. Another possible limitation is that the
study population was predominantly male (94 %) which
can further limit the generalizability of our findings.
Marino and colleagues found that both higher educational
level and male sex predict for a more rapid return to work
suggesting a possible underestimation in our study cohort.
[38] Further, 80 % of head and neck cancers are treated at
cancer centers nationally, suggesting the tertiary-referral
center may not bias the results toward higher
socioeconomic status as much as in other cancer sites
[39]. We did not ask for reasons for retirement; if some
participants retired earlier than planned because of their
health, this would increase the association between treat-
ment toxicities and poor employment outcomes. In
addition, while we asked about occupation, we did not
explicitly ask about education which makes direct com-
parison against prior studies more difficult. Future studies
should assess when participants began their time off from
work and reasons for stopping work or retiring, which
could further describe the trajectory of toxicity and subse-
quent recovery.
To our knowledge, this is the first study to look at
employment outcomes specifically in patients with HPV-
positive oropharynx cancer. Going into the survey, we
expected to find that patients treated with cisplatin-
based therapy would require more time to return to
work given the higher toxicities generally attributed to
this regimen. One possible explanation for our findings
is that physicians are able to judge tolerability and each
patient is pushed to their own extreme, and as a result,
all are normalized in the end to very symptomatic, with
no one regimen causing more harm in the end than
another. Alternatively, it may be that CTRT, as a treat-
ment, is simply toxic and requires time away from work
and that differences between regimens are not detectable
by a blunt instrument such as our retrospective analysis.
Unlike prior studies which have combined head and
neck cancer disease sites and treatment, this study fo-
cused on a specific subset of patients who all underwent
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study are reassuring in that the vast majority of patients
are able to return to work compared to historical head and
neck cancer patients. But even in this cohort, who gener-
ally is young and otherwise healthy at the time of diagnosis,
there are areas for concern. Treatment toxicities, including
dry mouth, sticky saliva, and weight changes, persist more
than a year after treatment completion in many patients,
and a subset of patients experiences prolonged employ-
ment interruption, an inability to return to work following
CTRT, and dissatisfaction with ability to work. The results
of this study will help patients and clinicians plan for the
impact of cancer treatment on employment and highlight
the on-going need for prevention, identification, and
management of late toxicities.
Conclusions
In this cross-sectional analysis of long-term survivors of
HPV-related oropharyngeal cancer treated with CTRT,
the majority of patients employed at baseline were able to
return to work after taking a break from employment.
However, almost all patients needed to take some time off
from work (median 14 weeks) or reduce responsibilities
during treatment, independent of baseline clinical or
sociodemographic characteristics or treatment variables.
There was a subset of patients who remained unsatisfied
with their ability to work over a year from treatment com-
pletion, and this dissatisfaction was associated with worse
functional and quality of life outcomes following CTRT
therapy. Improved long-term toxicity management could
therefore potentially enhance employment outcomes in
this growing cohort of cancer survivors.
Methods
We performed a cross-sectional survey regarding employ-
ment and quality of life among survivors of HPV-positive
oropharyngeal cancer. The study was approved by Institu-
tional Review Board at Memorial Sloan Kettering Cancer
Center (MSKCC), and all study participants provided
informed consent.
Participants
We recruited patients seen in outpatient medical oncology
or radiation oncology clinics at MSKCC from 2010
through 2014. Eligible patients had a pathologically con-
firmed oropharyngeal squamous cell carcinoma that was
positive for HPV (either by HPV ISH or p16 on IHC in a
CLIA approved laboratory), completed definitive CTRT at
least 12 months prior and remained without clinical
evidence of recurrence. The study team identified consecu-
tive patients meeting study eligibility criteria before sched-
uled follow-up appointments with a medical oncologist. Of
the 178 patients approached to participate, 5 patients re-
fused or withdrew consent and 29 were found ineligible(never returned survey or HPV-status not confirmed). The
sample was then limited to patients who reported full-
time employment at the time of diagnosis (n = 102).
Employment measures
The primary survey outcomes were related to employ-
ment at the completion of treatment and at the time of
survey. Self-reported occupation at cancer diagnosis was
categorized using the Unites States Equal Employment
Opportunity Commission Job Classification Guide [40].
Participants were asked about employment status at
completion of treatment, which was dichotomized as
working (full-time or part-time) or not working (retired
or unemployed). For those who returned to work, partic-
ipants were asked to report whether they reduced their
work hours, took time off from work, and if so, how
much time was taken. We dichotomized time to return
to work as longer than the median time for the cohort
(or no return) versus shorter. Participants were asked
about their current employment status, which was
categorized as working or not working. We also asked
participants about their satisfaction with their current
ability to work, with response options of satisfied or not
satisfied. In an open-ended item, participants could offer
reasons for dissatisfaction with ability to work.
Health-related quality of life measures
Health-related quality of life was estimated using the
EQ-5D a validated instrument assessing level of impair-
ment or function in five domains: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression.
We dichotomized responses to these items as any prob-
lems or no problems [41]. The EQ-5D also includes a
visual analogue scale (VAS) which asks participants is to
rate their current health on a scale from 0 to 100.
The European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire Head and Neck 35
module (EORTC QLQ-H&N35) was used to assess head
and neck cancer-specific quality of life. This instrument
assesses pain, swallowing, senses, speech, social eating, so-
cial contact, sexuality, problems with teeth, dry mouth,
sticky saliva, cough, trismus, weight loss, weight gain, use
of nutritional supplements, feeding tubes, and painkillers
[42]. The 35 items of the QLQ-H&N35 yield both multi-
item symptom scale scores and single-item symptom
scores, for a total of 18 distinct scores scaled from 0 to
100, with higher scores representing higher levels of
symptomatology/problems [43].
Covariates
Covariates included sociodemographic characteristics, dis-
ease and treatment characteristics, functional status, and
comorbidity score at diagnosis. Clinical and demographic
information (including age, sex, clinical stage, functional
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from the electronic medical records. Functional status was
measured by the Karnofsky Performance Score (KPS), ran-
ging from 70–100 %, with higher scores representing better
functional status. An age-adjusted modified Charlson co-
morbidity index score was calculated based on review of
physician notes, with scores ranging from 1 to 6 [44].
Statistical analysis
Patient characteristics and survey responses were ana-
lyzed using descriptive statistics, including frequencies,
means and medians. Bivariate analyses, using chi-square
and Fisher exact tests as appropriate, were performed
between sociodemographic, disease, treatment, and clin-
ical characteristics and the following outcomes: 1) no
return to work, 2) longer time to return to work and 3)
employment status at survey. We used multivariable lo-
gistic regression to evaluate whether sociodemographic,
disease, treatment, and clinical characteristics (specific-
ally age, marital status, stage, site, and chemotherapy)
were associated with longer time to return to work
(which included those who never returned to work).
However, due to the small number of events, we did not
use multivariable analysis to assess the relationship be-
tween sociodemographic, disease, treatment, and clinical
characteristics and ever returning to work.
As a secondary employment outcome, chi-square tests
were used to test the associations between satisfaction
with ability to work at time of survey and each of the
following predictors: EQ-5D global, self-care, usual activ-
ities, pain/discomfort and anxiety/depression responses.
Because of the skewness observed in self-rated current
health, the Mann–Whitney test was used to compare
scores from the EQ-5D VAS between those who were and
were not satisfied with their ability to work at the time of
survey. To address concerns associated with multiple
comparisons, we used a conservative p-value of ≤0.01 as
the threshold for statistical significance in analysis of
EORTC HN-35 scores [43]. All analyses were performed
using SAS version 9.4 (SAS Institute, Cary, NC).
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